Clinical trial
An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB
NCT00537537 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- Not reported
- Enrollment
- 100 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.